CDK4 and breast cancer: Among CDK4/6i, abemaciclib (ABE) is particularly active in metastatic endocrine-resistant patients, achieving an invasive disease-free survival advantage in the adjuvant treatment of high-risk hormone-sensitive BC [12,14,15,16].